Syndax Pharmaceuticals (SNDX) Tops Q1 EPS by 14c

Syndax Pharmaceuticals (NASDAQ: SNDX) reported Q1 EPS of ($0.48), $0.14 better than the analyst estimate of ($0.62). Revenue for the quarter came in at $64.9 million versus the consensus estimate of $71.84 million.

For earnings history and earnings-related data on Syndax Pharmaceuticals (SNDX) click here.

You May Also Be Interested In

• Cerebras CEO says investors misunderstood margin guidance
• Qualcomm to launch data center CPU in mid-2028 - Data Center Chief
• Active options: NVDA TSLA AMZN AAPL MSTR SPCX MU PLTR MSFT WEN SOFI